Advanced Enzyme Technologies Ltd (NSE: ADVENZYMES, BSE: 540025) is a Thane, Maharashtra-based company in the Enzymes and Industrial Biotechnology industry. With a market capitalisation of ₹3,151 Cr, it ranks #1,035 by market cap among the 6,197 Indian listed companies on FinBizNet. At ₹284.60 (as of 16 Nov 2026), the share price is 32.1% below its 52-week high of ₹419.00 and 15.3% above its 52-week low of ₹246.80. The share price is down 8.6% over one year and down 5.7% over three months.
| Current Price | ₹284.60 |
|---|---|
| Market Cap | ₹3,151 Cr |
| NSE Symbol | ADVENZYMES |
| BSE Code | 540025 |
| Sector | Materials > Chemicals > Speciality Chemicals |
| Sub-Industry | Specialty Chemicals > Enzymes and Industrial Biotechnology |
| P/E Ratio | 18.9 |
| Return on Equity | 11.02% |
| Return on Assets | 6.85% |
| 52-Week Range | ₹246.80 – ₹419.00 |
| 1-Year Price Change | -8.6% |
| 3-Month Price Change | -5.7% |
| Beta (1Y) | 0.32 |
| Dividend Yield | 0.95% |
| Headquarters | Thane, Maharashtra |
| Website | www.advancedenzymes.com |
| Revenue | ₹215 Cr |
|---|---|
| Net Profit | ₹51 Cr |
| Net Margin | 23.8% |
| EPS (Basic) | ₹4.33 |
| Basis | consolidated |
Figures in ₹ crore, parsed from the company's exchange filing (XBRL).
Advanced Enzyme Technologies Ltd reported revenue of ₹215 Cr in Q2 FY27, up 16.2% from ₹185 Cr in Q2 FY26 and up 13.0% from ₹190 Cr in Q1 FY27. It posted a net profit of ₹51 Cr for the quarter, against a net profit of ₹45 Cr in Q2 FY26 (up 14.4%). Across the 7 quarters from Q4 FY25 to Q2 FY27, quarterly revenue ranged from ₹167 Cr (Q4 FY25) to ₹215 Cr (Q2 FY27). The company was profitable in each of these 7 quarters.
| Quarter | Revenue | Net Profit | Net Margin |
|---|---|---|---|
| Q2 FY27 | ₹215 Cr | ₹51 Cr | 23.8% |
| Q1 FY27 | ₹190 Cr | ₹39 Cr | 20.3% |
| Q4 FY26 | ₹203 Cr | ₹45 Cr | 22.3% |
| Q3 FY26 | ₹172 Cr | ₹43 Cr | 25.1% |
| Q2 FY26 | ₹185 Cr | ₹45 Cr | 24.2% |
| Q1 FY26 | ₹186 Cr | ₹40 Cr | 21.8% |
| Q4 FY25 | ₹167 Cr | ₹27 Cr | 16.0% |
Consolidated figures (₹ crore, XBRL filings).
Promoters held 43.56% of Advanced Enzyme Technologies Ltd's shares as of Sept 2026, against 43.07% in Sept 2025 (+0.49 percentage points). Delivery averaged 55.7% of traded volume across 16 NSE sessions (22 Oct 2026 – 13 Nov 2026).
Advanced Enzyme Technologies Limited, together with its subsidiaries, engages in the research, development, manufacture, and marketing of enzymes and probiotics in India, Europe, the United States, Asia, and internationally. The company offers enzymes and probiotics-based nutritional supplements for human healthcare and nutrition, animal nutrition, fruit and vegetable processing, baking, brewing and malting, starch and grain processing, protein modification, yeast processing, dairy and cheese processing, and oils and fats processing, as well as for specialty applications, biofuels, and bio-catalysis. It also provides non-food processing enzymes for textile, leather, and pulp and paper processing, as well as detergents and cleaning aids. The company was formerly known as Advanced Biochemicals Limited and changed its name to Advanced Enzyme Technologies Limited in 2005. Advanced Enzyme Technologies Limited was founded in 1957 and is headquartered in Thane, India.
1. Manufacturing and Sales of Enzymes-This segment researches and develops, manufactures, and markets enzymes and probiotics.
1. Manufacturing and Sales of Enzymes-100%
Advanced Enzyme Technologies Ltd is trading at ₹284.60, with a market capitalisation of ₹3,151 Cr.
Advanced Enzyme Technologies Ltd operates in the Materials > Chemicals > Speciality Chemicals space (Specialty Chemicals > Enzymes and Industrial Biotechnology).
Advanced Enzyme Technologies Ltd has a P/E of 18.9 and a return on equity of 11.02%.
Advanced Enzyme Technologies Ltd is listed on the NSE under the symbol ADVENZYMES and on the BSE under the scrip code 540025.
Advanced Enzyme Technologies Ltd's share price is down 8.6% over one year and down 5.7% over three months. Its 52-week range is ₹246.80 to ₹419.00.
In Q2 FY27, Advanced Enzyme Technologies Ltd reported revenue of ₹215 Cr and net profit of ₹51 Cr, with basic EPS of ₹4.33 (consolidated, parsed from the company's exchange filing).
Advanced Enzyme Technologies Ltd reported revenue of ₹215 Cr in Q2 FY27, up 16.2% from ₹185 Cr in Q2 FY26 and up 13.0% from ₹190 Cr in Q1 FY27.
Promoters held 43.56% of Advanced Enzyme Technologies Ltd's shares as of Sept 2026, against 43.07% in Sept 2025 (+0.49 percentage points).
Data as of 16 Nov 2026. Descriptive market data only — not investment advice.